In his role as VP, Pharmaceutical Technology & Innovation, Gjalt Huisman is responsible for exploring new application opportunities for Codexis’ CodeEvolver® technology in the pharma industry. The first asset developed under this initiative is an orally stable enzyme for potential treatment of phenylketonuria, PKU. Gjalt has led numerous projects in which new biocatalytic processes were developed, including for blockbuster pharmaceuticals, such as atorvastatin, simvastatin and sitagliptin. Gjalt received his Ph.D. from the University of Groningen (NL) and was a post-doc at Harvard Medical School.
.svg)
